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Ras expression in human epithelial cells with integrated HPV genomes has been shown to cause tumorigenic transformation. The effects of Ras
in cells representing early stage HPV-associated disease (i.e., when HPV is extrachromosomal and the oncogenes are under control of native
promoters) have not been examined. Here, we used human cervical keratinocyte cell lines containing stably replicating extrachromosomal HPV-16
and present the novel finding that these cells resist transformation by oncogenic H-Ras. Ras expression consistently diminished anchorage-
independent growth (AI), reduced E6 and E7 expression, and caused p53 induction in these cells. Conversely, AI was enhanced or maintained in
Ras-transduced cervical cells that were immortalized with a 16E6/E7 retrovirus, and minimal effects on E6 and E7 expression were observed. Ras
expression with either episomal HPV-16 or LXSN-E6/E7 was insufficient for tumorigenic growth suggesting that other events are needed for
tumorigenic transformation. In conclusion, our results indicate that Ras-mediated transformation depends on the context of HPV oncogene
expression and that this is an important point to address when developing HPV tumor models.
© 2006 Elsevier Inc. All rights reserved.Keywords: Ras; Episome; Extrachromosomal; Episomal HPV; Papillomavirus; HPV; Transformation; Anchorage independence; Cervical keratinocyteIntroduction
High-risk human papillomavirus (HPV) infection is a
causative agent of cervical cancer, with nearly all malignancies
containing HPV DNA (Walboomers et al., 1999). During the
natural course of infection, HPV is first established as an
extrachromosomally replicating genome (often referred to as
episomal replication) in the basal cells of stratifying epidermis.
The association of the E6 and E7 oncogenes with several
cellular factors, like the tumor suppressor p53, the hTERT
catalytic component of telomerase, and the retinoblastoma (Rb)
protein, promotes cellular immortalization and transformation
(Mantovani and Banks, 2001; Munger et al., 2001).⁎ Corresponding author. Fax: +1 319 353 4556.
E-mail address: al-klingelhutz@uiowa.edu (A.J. Klingelhutz).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.07.039Progression to malignancy is commonly associated with
transcriptional upregulation of E6/E7 as a result of integration of
the viral genome with preferential deletion of the E1 and E2
ORFs (Andersson et al., 2005; Romanczuk and Howley, 1992).
Many studies have relied on the use of cloned HPV E6 and E7
genes artificially expressed from a retroviral or CMV promoter
to mimic HPV-infected cells and the use of extensively cultured
cell lines that contain integrated HPV to model advanced
cervical disease. Models of HPV transformation based on these
systems, however, do not consider that a significant number of
cervical lesions, even some high grade, continue to maintain
extrachromosomal copies of the viral genome.Arias-Pulido et al.
showed that integration most commonly occurs in the presence
of a multitude of HPVepisomes (Arias-Pulido et al., 2006), and
in light of a recent report, viral genes expressed episomally,
namely E2, likely influence expression from integrated HPV
DNA in a natural infection (Pett et al., 2006). Themaintenance of
69K.L. Berger et al. / Virology 356 (2006) 68–78extrachromosomal genomes and its effect on oncogene regula-
tion, both in cis and trans, are important considerations for
understanding how high-risk HPV malignancies develop.
Examination of the early stages of HPV infection and
transformation has relied on the establishment of viral
replication in vitro. These studies have been hindered by the
tendency of viral genomes to integrate during cell culture,
although a handful of reports have demonstrated stable
episomal replication of HPV-11, -16, -18, -31, and -45 in
foreskin keratinocytes (Flores et al., 1999; Frattini et al., 1996,
1997; McLaughlin-Drubin et al., 2003; Thomas et al., 2001)
and HPV-18 in cervical keratinocytes (Meyers et al., 1997).
Study of episomal HPV-16 specifically in cervical keratinocytes
has relied on the use of W12 cells and its subclonal derivations.
W12 cells were isolated from a pre-existing CIN I lesion
(Stanley et al., 1989), and early passage cells from the parental
cell line maintain episomal copies of HPV-16 which are
susceptible to integration over time (Jeon et al., 1995). We
previously reported the in vitro establishment of episomally
replicating HPV-16 in isogenic cell lines derived from primary
human cervical keratinocytes by transfection of HPV-16
genomes isolated from W12 clone E or by a novel adenoviral
vector (Lee et al., 2004; Sprague et al., 2002). The cell lines
were isolated from independently derived clones soon after
introduction of HPV into primary cells. Extrachromosomal
replication of HPV-16 in these cells is quite stable when
cultured with irradiated feeder fibroblasts (Sprague et al., 2002).
Thus, the HPV-positive cell lines generated in vitro provide a
model of early stage cervical disease to study malignant
progression of HPV-16-infected cells by factors such as
oncogenic Ras.
Ras is a cellular GTPase that signals through MAPK, PI3K,
and Ral-GEF pathways (Katz and McCormick, 1997). Ras
expression in primary fibroblasts induces growth arrest and a
flattened, enlarged phenotype characteristic of premature
senescence (Mason et al., 2004; Serrano et al., 1997). Murine
keratinocytes (Lin et al., 1998), human ovarian surface
epithelial cells (Nicke et al., 2005), and human esophageal
keratinocytes (Takaoka et al., 2004) react similarly. However, it
has been reported that human thyroid epithelial cells proliferate
upon introduction of Ras (Skinner et al., 2004), suggesting that
the effects of Ras on proliferation are cell type specific. In cells
where Ras mediates senescence, it is generally accepted that
senescence is caused by activation of the ARF-p53 and
p16INK4a pathways which trigger cell cycle arrest in G1
(Ferbeyre et al., 2002; Lin et al., 1998; Serrano et al., 1997).
This response is considered a tumor suppressing mechanism to
prevent aberrant cell signaling and proliferation. Unlike rodent
cells, human diploid fibroblasts require disruption of both p53
and p16INK4a pathways to overcome senescence (Serrano et al.,
1997). Esophageal keratinocytes lacking a functional p53
pathway (Takaoka et al., 2004) or hTERT-immortalized
human adenoid epithelial cells lacking p14ARF (Farwell et al.,
2000) undergo Ras-induced senescence, further supporting that
disruption of the ARF-p53 pathway alone is insufficient for
human cells to escape growth arrest. The contribution of
p16INK4a in Ras-induced senescence in epithelial cells is lessclear. In one study, overexpression of Cdk4 (which counteracts
p16INK4a) in human epidermal keratinocytes was sufficient for
Ras-mediated transformation (Lazarov et al., 2002) while
hTERT-immortalized human foreskin keratinocytes deficient
for p16INK4a remained sensitive to Ras oncogene expression
(Farwell et al., 2000).
Constitutive activation of the Ras signaling pathway is an
important component of malignant progression for a number of
different cancers. Overexpression or mutation of Ras has been
identified to varying degrees in cervical cancers depending on the
experimental design (reviewed inMammas et al., 2005). Several
studies indicate an association of Ras with high-grade cervical
lesions (Alonio et al., 2003; Bernard et al., 1994; Riou et al.,
1988; Sagae et al., 1990). Alonio et al. detectedmutatedH-Ras in
20%ofCIN III cases and 41%of in situ carcinomas (Alonio et al.,
2003). In another study, elevated Ras expression was detected in
17.9%ofCIN I lesions as compared to 53.9%ofCIN III (Sagae et
al., 1990). There are also reports that Ras alterations rarely occur
in cervical cancer, however, and these studies conclude that there
is no correlation between disease severity and Ras expression
(Ngan et al., 1999; O'Leary et al., 1998; Van Le et al., 1993).
Thus, it is unclear at what stage Ras overexpression or mutation
occurs during malignant transformation and whether HPV
episome-containing cells tolerate constitutive activation of the
Ras pathway, since there was no distinction between episomal or
integrated HPV in the studies mentioned.
It is understood that HPV infection alone is not sufficient for
tumor formation and that carcinogenesis is a multistep process
(reviewed in Hanahan and Weinberg, 2000). In rodent models,
Ras has been shown to cooperate with oncogenes from HPV in
vivo by inducing tumor growth in HPV-16 E6/E7 transgenic
mice (Schreiber et al., 2004). In human cells, understanding the
contribution of Ras to cellular transformation in the context of
the full HPV genome has been limited to studies using constructs
which integrate. Integrated HPV constructs have been shown to
cooperate with H-Ras or K-Ras in cervical keratinocytes
(DiPaolo et al., 1989), foreskin keratinocytes (Durst et al.,
1989, 1991), and prostate epithelial cells (Rhim et al., 1994) by
inducing tumor growth in mice. Retroviral transductions using
only the 16-E6/E7 oncogenes, however, along with H-Ras and
hTERT in fibroblasts and HEK cells did not result in anchorage
independence or tumor growth (Hahn et al., 2002; Morales et al.,
1999), indicating other events or the full HPV genome are
necessary for malignant transformation in those tumor models.
Because there is a lack of understanding of cancer
progression based on Ras and cervical keratinocytes maintain-
ing HPV-16 DNA extrachromosomally, we utilized clonal cell
lines generated in our laboratory to examine whether oncogenic
Ras cooperates with stable episomal HPV-16, specifically
during the early stages of transformation. Since we also
generated clonal cell lines derived from the same genetic
background as the episomal cells using LXSN-16E6/E7 retro-
virus, we were able to compare the effects of Ras between two
different contexts of oncogene expression. While Ras enhanced
or maintained anchorage independence of E6/E7-transduced
cells, our results demonstrate that Ras actually caused a loss in
transformation potential of cells containing HPV-16 episomes.
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Ras-induced transformation commensurate with reduction of
E6 and E7 and induction of p53.
Results
Ras expression does not alter episome copy number
Since no in-depth study has analyzed whether Ras and
episomal HPV-16 cooperate in transformation of human
cervical cells, we grew clonal cervical keratinocyte cell lines
containing HPV-16 episomes, called HPVEP cells, and trans-
duced them with H-RasG12V. We also used isogenically derived
clonal cell lines transduced with LXSN-16E6/E7, called E6/
E7LX cells, as well as primary human cervical keratinocytes
(HCKs). Ras protein expression was confirmed by Western blot
(Fig. 1A). The H-RasG12V construct used in our studies
produces a functional protein capable of stimulating the Ras
pathway in both HPVEP and E6/E7LX cells, as evidenced by
increased phosphorylation of MEK and MAPK effector
proteins (Fig. 1B). The reason for higher basal levels of
phosphorylated p44/42 MAPK in the E6/E7LX cells is unknown
but may have to do with higher expression levels of E6 in these
cells (Chakrabarti et al., 2004). To verify that Ras did not disrupt
episome copy number control or cause integration, Southern
analysis was performed (Fig. 1C). Even in the presence of high
Ras expression, HPVEP cells maintained stable episomal DNAFig. 1. (A) Western blot verifying Ras protein expression one passage after
retroviral transduction of pBabe-puro H-RasG12V (Ras) or pBabe-puro vector
(V). Cell lines used are HPVEP clones (B, F, and G), E6/E7LX clones (#2, #5, and
#6), or primary HCKs. (B) Western blot verifying functionality of the H-RasG12V
construct by activation of downstream effectors via phosphorylation of MEK1/2
and 44/42 MAPK proteins in HPVEP and E6/E7LX cells. (C) Southern blot
displaying viral DNA present in HPVEP clonal populations expressing Ras or
vector. Cells were cultured for 10 passages (∼20 population doublings) after
Ras-retrovirus infection and DNA was digested either with BglII (− lanes) or
BamHI (+ lanes). BglII cleaves cellular genomic DNA, leaving the HPV
genome as an intact supercoiled episome (c) or nicked-circular plasmid (a).
BamHI linearizes the HPV genome (b). Picogram quantities of linearized
HPV-16 plasmid were used to estimate copy number as previously described
(see Materials and methods). The 30 pg lane is equivalent to 5 copies per cell.for at least 20 population doublings after Ras transduction with
equivalent copies between Ras-transduced cells and vector
controls. We have also observed episome maintenance with no
evidence of integration in untransduced HPVEP cells even when
grown for ∼30 population doublings on plastic without
irradiated feeders, thought necessary for episome stability, in
serum-free keratinocyte media (data not shown). This finding
along with Fig. 1C demonstrates the notable stability of
episomes in the HPVEP cells created from primary cervical
keratinocytes.
Effects of Ras on cell growth
Because Ras is capable of inducing senescence in some cells
and stimulating growth in others (Skinner et al., 2004), we first
examined whether expression of mutated Ras induced morpho-
logical changes indicative of senescence in the HPVEP and E6/
E7LX cells. Functionality of the H-Ras
G12V retroviral construct
used in our study was further confirmed in primary HCKs as
indicated by the presence of enlarged, highly vacuolated cells
typical of senescence-associated morphology (Fig. 2A). Ras-
HPVEP cells did not exhibit as dramatic of an effect, although
there were sporadic populations of enlarged, senescent-like cells
(Fig. 2A). Differences between Ras and vector transduced E6/
E7LX were not readily apparent (Fig. 2A). We stained for
senescence-associated beta-galactosidase (SA-β-gal) activity, a
marker that is commonly observed in senescent fibroblasts, but
detected only weak SA-β-gal staining in late passage senescent
primary keratinocytes and Ras-expressing clones (data not
shown), suggesting that this is not a reliable marker for
senescence in keratinocytes. To quantify the senescent-like
cells, a blinded count of cells with an enlarged morphology was
performed (Fig. 2B). Senescent-like cells were more frequently
found in the Ras-HPVEP cultures than vector control. To a lesser
extent, a small fraction of senescent-like cells was also counted
in the Ras-E6/E7LX cultures as compared to vector. We also
examined the cells for changes in cell cycle profile and did not
see dramatic differences between Ras and vector controls in
either cell type (data not shown). We next examined the effect of
Ras on population doubling (PD) time based on growth assays in
monolayer culture (Fig. 3). Ras lengthened the PD time of two
HPVEP clones by 4% in clone B and 8% in clone F, yet had no
effect in clone G. Two of three E6/E7LX clones had decreased PD
time upon Ras expression (i.e., a 3% decrease in PD time for
Ras-E6/E7LX clone #6 and only a 1% decrease for Ras-E6/E7LX
clone #5). No difference in PD time was observed for E6/E7LX
clone #2. In summary, Ras expression had a negative but small
effect on growth of HPVEP cells in monolayer culture, and
growth of E6/E7LX clones was either enhanced or unchanged.
Ras reduces transformation potential of HPVEP but not E6/E7LX
cells
Growing cells in soft agar is a common in vitro transforma-
tion assay that measures anchorage-independent (AI) growth
(i.e., the ability to grow without substrate attachment). To test if
Ras altered anchorage independence of the HPVEP and E6/E7LX
Fig. 2. (A) Microphotographs of morphological changes induced by H-RasG12V. Photographed cultures of HPVEP clone G, HPVEP clone #2, and HCKs were grown
without irradiated feeders. Black arrows point to enlarged cells in Ras-expressing HPVEP cells, which are rarely found in E6/E7LX cultures. HCKs demonstrate typical
morphology induced by oncogenic Ras in primary epithelial cells. (B) Blinded counts of enlarged and flattened cells, indicative of senescence, from triplicate plates of
either HPVEP clone G or HPVEP clone #2 are expressed as a percentage of the total number of cells counted. Data are expressed as the mean±SD.
Table 1
The effect of H-RasG12V on colony-forming efficiency in soft agar and tumor
growth
Cell line Clone
construct
Anchorage
independence
(Experiment #1) a
Anchorage
independence
(Experiment #2)
No. of mice
with tumors
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assay. Two experiments were performed (Table 1) using cell
lines generated from two independent transductions with Ras
and vector. For visualization purposes, the results of the first
experiment are shown graphically (Fig. 4). AI growth of both the
HPVEP and E6/E7LX clones was heterogenous, with vector
controls ranging from 1 to 16% CFE (Fig. 4). More striking than
the growth changes induced by Ras in monolayer cultureFig. 3. Population doubling (PD) time was determined over a 3-day period from
absorbance data generated from crystal violet staining of cultures (see Materials
and methods). H-RasG12V increased PD time in two of three HPVEP clones. No
change in PD time was observed for two E6/E7LX clones, #2 and #5, while Ras
slightly decreased PD time in one cell line, clone #6. Data are expressed as the
mean±SD of triplicate data points.
% CFE±SD % CFE±SD
HPVEP B-Ras 9.5±1.8 5.2±1.0 0/3
B-vector 14.6±0.6 12.0±1.0 0/3
F-Ras 3.4±0.9 1.0±0.7 0/3
F-vector 6.3±0.8 9.6±1.4 0/3
G-Ras 2.3±0.3 2.1±0.1 0/3
G-vector 15.8±3.4 6.8±2.8 0/3
E6/E7LX #2-Ras 7.1±0.6 2.5±0.5 0/3
#2-vector 3.7±0.5 0.9±0.2 0/3
#5-Ras 8.1±0.8 7.0±0.7 0/3
#5-vector 8.4±1.1 7.8±0.7 0/3
#6-Ras 22.1±2.2 12.8±1.0 0/3
#6-vector 11.8±1.3 3.7±0.6 0/3
Control HPV-18
tumor b
N/D±N/D N/D±N/D 3/3
C33A 7.1±0.5 N/D±N/D N/D
HCK 0±0 0±0 0/3
a Experiment #1 is graphed in Fig. 4.
b 1811-NMU cells; N/D=not determined.
Fig. 5. Real-time RT-PCR for E6 transcripts in Ras or vector-transduced HPVEP
(A) or E6/E7LX cells (B) and E7 transcripts in HPVEP (C) or E6/E7LX cells (D)
all standardized to 18S mRNA levels. HPVEP cells contain the full genome
derived fromW12-E cells. E6/E7LX cells dually express E6 and E7 from a single
retroviral promoter. For reference, RNA levels were calculated relative to W12
cervical cells, the cell line containing episomal HPV-16 from which the W12-E
clone was derived. Data are expressed as the mean±SD of triplicate data points.
Fig. 4. H-RasG12V significantly reduced anchorage-independent (AI) colony
formation of all HPVEP clones (**p<0.001) and stimulated growth of two E6/
E7LX clones (**p<0.001). Percent colony forming efficiency (%CFE) is
reported as the percentage of colonies that grew in soft agar per number of cells
initially seeded. HPV-negative C33A cells (+) control; primary HCKs (−)
control. Data are expressed as the mean±SD of triplicate data points.
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Oncogenic Ras significantly limited AI growth of all three
HPVEP cell lines (p<0.001) (Fig. 4). In contrast, two E6/E7LX
clones (#2 and #6) showed significant growth enhancement
upon Ras expression (p<0.001) while one cell line (#5) showed
no difference (Fig. 4). The lack of enhanced anchorage
independence by Ras in E6/E7LX clone #5 likely reflects
heterogeneity in E6/E7LX cell clones. Overall, our results
indicate that Ras can cause different effects on AI growth
depending on whether cells contain episomal HPV-16 or the
16E6/E7 retroviral construct.
Since AI growth does not necessarily correlate to an ability
to form tumors in vivo, full transformation of human cells is
typically determined by injecting cells into immuno-compro-
mised mice. Therefore, we tested whether Ras could cooperate
with episomal HPVor LXSN-E6/E7 to form tumors in athymic
nude mice after subcutaneous injection. After 100 days post-
injection, no tumorigenic growth was observed for HPVEP or
E6/E7LX cells expressing Ras or vector (Table 1), indicating that
Ras and expression of E6/E7 are insufficient for causing
tumorigenic transformation.
Effects of Ras on HPV oncogene expression
To determine whether differential oncogene expression is
responsible for the observed differences between the HPVEP and
E6/E7LX cells, we used real-time RT-PCR to measure the
abundance of E6 and E7 mRNA. For reference, mRNA levels
were calculated relative to W12 cells. Vector control HPVEP
cells, which contain W12-E genomes, had comparable amounts
of E6 and E7 to the parental W12 cell line (Figs. 5A and C).
Clearly, vector control E6/E7LX cells expressedmore E6 than the
HPVEP vector control cells (13-fold more on average) (Figs. 5A
and B; note different scales). Interestingly, the HPVEP and E6/
E7LX vector control cell lines had comparable amounts of E7
mRNA with E6/E7LX vector controls expressing only 1.6-fold
more on average (Figs. 5C and D). In agreement with previous
reports, this supports the finding that the dual LXSN-E6/E7retroviral construct expresses E7 inefficiently (Halbert et al.,
1991). These results indicate that E6 expression is one key
distinction between HPVEP and E6/E7LX cell types.
Interestingly, we found that Ras reduced E6 mRNA levels in
the HPVEP clones (Fig. 5A). However, Ras expression affected
E6 transcripts in only one of three E6/E7LX clones (#6), where it
actually increased levels (Fig. 5B). Similar results were attained
for E7. Ras reduced E7 transcripts in the HPVEP clones (Fig. 5C)
but did not have a significant effect on E7 transcript levels in E6/
E7LX clones #2 and #5 and marginally increased levels in E6/
E7LX clone #6 (Fig. 5D). Since we observed changes in E7
Fig. 6. Western blot of p53, HPV16-E7, and p16INK4a proteins in HPVEP and
E6/E7LX clonal populations. Primary HCKs were used for reference. Lanes
consist of lysates collected one passage after transduction and selection for
H-RasG12V or vector (V).
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levels (Fig. 6). In HPVEP cells, Ras reduced E7 protein and this
corresponds to the reduction of E7 mRNA shown in Fig. 5B.
With the E6/E7LX clones, some reduction of E7 protein was
observed upon Ras expression but, overall, this was not as great
as that observed for the HPVEP cells. The reason for the slight
differences between E7 transcript (Figs. 5B and D) and protein
levels (Fig. 6) is unknown. Since reliable antibodies for E6 are
not available, we were unable to assay for E6 protein in our cells.
Overall, however, our real-time RT-PCR and Western data
provide evidence that Ras represses expression of E6 and E7 in
HPVEP cells but has minimal effects in E6/E7LX cells.
Oncogenic Ras induces p53 but not p16INK4a in cells with
episomal HPV-16
Mutant Ras has been shown to upregulate p53 and p16INK4a
in normal human fibroblasts, resulting in growth inhibition and
senescence (Serrano et al., 1997). Since we observed
senescent-like cells, reduction in AI growth, and changes in
E6 and E7 transcript levels upon Ras transduction we examined
expression of p53 and p16INK4a in our different cell lines.
Western analysis was performed using protein lysates from
early passage cells (i.e., within 1 to 2 passages after
transduction of vector or Ras). As expected from basal levels
of E6 mRNA (Figs. 5A and B), HPVEP cells have higher p53
basal expression than E6/E7LX cells (Fig. 6). An increase in
p53 protein was detected in Ras-HPVEP cells (Fig. 6),
corresponding to a decrease in E6 mRNA. Changes in p53
were not evident between Ras-E6/E7LX and vector controls and
this is likely related to higher levels of E6 mRNA in these cells.
Since disruption of the p16INK4a pathway is sufficient to
overcome Ras-induced senescence in some epithelial cell types
(Lazarov et al., 2002) but not in others (Farwell et al., 2000),
we also examined p16INK4a protein levels. p16INK4a in either
cell type was unchanged upon Ras expression, indicating that
induction of p16INK4a was not associated with inhibition of AI
growth by Ras in HPVEP cells.
Discussion
The use of cervical cell lines with stably replicating HPV-16
extrachromosomal genomes allowed us to examine the effects
of Ras in cells that more closely resemble early HPV infection.
The finding that episomal HPV-16 does not support Ras-
mediated transformation in human keratinocytes indicates thatHPV genome status has a significant impact on transformation
capacity. HPV E6 and E7 oncogenes are essential for
transformation and the downregulation of both E6 and E7 by
Ras may partially explain why HPVEP cells have reduced AI
growth when Ras is introduced. Because p53 closely regulates
cell growth and can induce senescence, the significant
inhibition of AI growth is likely related to p53 upregulation
by Ras. Together, increased p53 and decreased E6 and E7 may
limit the growth of HPVEP cells in tissue culture and in soft agar.
The results with HPVEP cells contrast with those obtained from
cells expressing E6/E7 from a retroviral construct. The E6/E7LX
cells were able to maintain or enhance anchorage independence
likely because Ras expression did not profoundly affect p53,
E6, and E7 levels. Because of the skewed oncogene expression
favoring E6 transcription from the heterologous promoter in the
E6/E7LX cells, we speculate that it was artificial overexpression
of E6 and not E7 that specifically contributed to maintenance of
the transformed phenotype in the presence of Ras. Therefore,
we conclude that the context of oncogene expression may be a
determinant for transformation by oncogenic Ras.
Not uncommon for some transformed cells (Bihani et al.,
2004), our cell lines may retain properties of primary cells which
trigger tumor suppressing mechanisms, as in p53 induction in
Ras-HPVEP cells. It has been previously shown that oncogenic
Ras synergizes with integrated HPV-18 in HeLa cells by
stimulating cell cycle progression (Cordova-Alarcon et al.,
2005), but it was also noted in a related paper that a
subpopulation of Ras-transduced HeLa cells have aberrant,
giant cell morphology and underwent “mitotic death” (Miranda
et al., 1996). Thus, even HeLa cells may still retain some normal
responses to Ras. Interestingly, it has been noted, using reporter
constructs and HeLa cells, that Ras can mediate activation of the
HPV-18 viral upstream regulatory region (URR) (Medina-
Martinez et al., 1997). Regarding integrated HPV-16, one report
showed increased E6/E7 RNA expression in CX16-2 cells with a
human H-Ras oncogene (Gaiotti et al., 2000) while another
study reported no change in E6/E7 protein levels in the same
CX16-2 cells using a viral H-Ras homolog (DiPaolo et al.,
1989). We conclude that the effects of Ras on E6 and E7 RNA
and protein levels vary depending on HPV type, source of
oncogenic Ras, and most importantly, the context of oncogene
expression either from integrated HPV, integrated HPV
constructs containing non-HPV DNA sequences, or extra-
chromosomal genomes as shown here. A mechanism of how
Ras regulates E6/E7 is not fully understood but may involve
regulation of AP-1 transcription factors such as c-Jun and c-Fos
or other factors (Medina-Martinez et al., 1997).
As with p53, p16INK4a is another protein associated with
senescence (Serrano et al., 1997). Although we have observed
weak p16INK4a induction by Ras in primary cervical keratino-
cytes (unpublished data), Ras did not alter p16INK4a expression
in the HPVEP or E6/E7LX cells (Fig. 6). This is likely due to the
fact that Rb inactivation by E7 causes misregulation of the
p16INK4a pathway leading to high accumulation of p16INK4a
protein (Giarre et al., 2001), thus overshadowing any effect by
Ras. Therefore, while growth inhibition of HPVEP cells may be
in part due to p53 induction, it does not appear to be due to Ras
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E6 and E7, besides inactivation of p53 and pRb, may play a
role in Ras-mediated effects on AI growth. Both E6 and E7
bind to a plethora of cellular proteins and these interactions
may be important for maintaining or even promoting cell
growth upon Ras activation (Mantovani and Banks, 2001;
Munger et al., 2001). Further work is necessary to determine
what functions of E6 and/or E7 are important for allowing
transformation by Ras.
The answer to why Ras reduces transformation of cells with
episomal HPV-16 may also not be as simple as changes in
expression levels of E6 and E7. In our studies, E6 and E7
mRNA levels do not strictly correlate to %CFE in the AI growth
assays. For example, there is a notable increase in AI of E6/
E7LX clone #6 by Ras (Fig. 4) yet this clone expresses lower
amounts of oncogenes than the other E6/E7LX clones (Fig. 5).
There may be a heterogeneous response to Ras in E6/E7LX cells
or any number of other unknown cellular defects that could
have occurred in this cell line. In addition to expression levels,
whether Ras inhibits or enhances AI growth may also depend on
spliced E6 mRNA species. Transcription of the E6 ORF
produces alternatively spliced E6* in addition to full-length E6.
The function of E6* is unclear but may regulate E6/E7
expression (Sedman et al., 1991) and inhibit degradation of p53
by unspliced E6 (Pim et al., 1997). Studies have shown that
cells with extrachromosomal HPV genomes contain more
spliced E6 than unspliced (Doorbar et al., 1990; Hummel et al.,
1992). This could account for the lower levels of full-length E6
detected in the W12 and HPVEP cells in our assays. The over-
abundance of full-length E6 in the E6/E7LX cells suggests that
the LXSN-16E6/E7 construct is partially dysfunctional in its
ability to make the spliced forms. Enhancement of AI growth by
Ras in E6/E7LX and not HPVEP cells could also be due to
genetic variations in the oncogenes. HPVEP cells contain HPV-
16 genomes derived from W12-E (GenBank accession no.
AF125673) whereas LXSN-16E6/E7 contains sequences from
the prototype genome (GenBank accession no. K02718).
Sequence analysis reveals a deviation in W12-E from the
prototype—a codon change at amino acid 83 in E6. E6 variants
occur in nature and are epidemiologically linked to progression
of high-grade lesions to invasive cancers (Zehbe et al., 1998).
The E6 amino acid 83 variant (or E6 L83V) does not differ from
prototype in ability to degrade p53 but does enhance MAPK
signaling (Lichtig et al., 2006; Zehbe et al., 1998), and this may
affect the ability of cells to be transformed by Ras.
Certainly, other HPV proteins besides E6 and E7 could play
a role in the response of HPVEP cells to Ras. It is possible, for
example, that loss of E2 by integration of the HPV genome
constructs in previous studies with Ras (DiPaolo et al., 1989;
Durst et al., 1989, 1991; Rhim et al., 1994) or lack of E2 in our
E6/E7LX cells played a role in Ras-transformation. Gammoh et
al. showed that E2 inhibits transformation by HPV-16 E7 and
Ras in rodent cells (Gammoh et al., 2006). E2 may similarly
effect the ability of E6 to cooperate with Ras via transcriptional
regulation as well as protein interaction and mislocalization
(Grm et al., 2005). In our HPVEP cells, E2 may be limiting the
transformation potential of E6 and E7 through protein–proteininteractions, mislocalization, and/or repression of transcription,
thereby rendering cells more susceptible to Ras-induced growth
inhibition than cells without E2.
Several epidemiological studies have reported higher levels
of Ras in advanced cervical lesions (reviewed in Mammas et al.,
2005) and experimental data show that Ras stimulates
malignant transformation of human cells containing integrated
high-risk HPV (DiPaolo et al., 1989; Durst et al., 1989, 1991;
Rhim et al., 1994). Since high-grade lesions are often associated
with integration and upregulated oncogene transcription while
low-grade lesions more commonly contain extrachromosomal
HPV, mutations in Ras may only be tolerated by cells
expressing high levels of E6 and E7. Since advanced lesions
harboring integrated DNA likely also contain episomal DNA
(Arias-Pulido et al., 2006) and also since episomal E2
expression can affect regulation of integrated viral sequences
(Pett et al., 2006), episomal HPV may still prevent Ras-
mediated transformation even when integrated HPV is present.
These hypotheses would require further testing using similarly
derived episomal and integrated cell lines. Since our experi-
ments were performed using a retroviral construct that expresses
high levels of H-RasG12V, we also cannot rule out the possibility
that lower levels of mutated H-Ras from the endogenous
promoter could lead to enhanced transformation in HPV-
infected cells (Hua et al., 1997).
Not surprisingly, cervical cells expressing Ras with episomal
HPV-16 or overexpressed 16E6/E7 do not form tumors in mice.
In HPV tumor models, Ras has only been shown to induce
tumor growth of cells containing integrated genomes (DiPaolo
et al., 1989; Durst et al., 1989, 1991; Rhim et al., 1994) or by
crossing Ras transgenic mice with E6/E7 transgenic mice
(Schreiber et al., 2004). Our analysis of cervical keratinocytes
agrees with Morales et al. and Hahn et al. who demonstrated
that E6/E7 overexpression, hTERT, and Ras were insufficient
for tumor growth of human cells in mice (Hahn et al., 2002;
Morales et al., 1999). The addition of SV40-small t antigen was
required for tumorigenesis (Hahn et al., 2002; Uren et al., 2005).
SV40-small t antigen is known to affect the MAP kinase
pathway and also inhibit protein phosphatase 2A. Since our cell
lines already have active telomerase (Sprague et al., 2002), it
would be of interest to determine whether expression of small t
might be sufficient for tumor growth in conjunction with Ras
expression. Furthermore, in some cervical cancer specimens,
Myc, ErbB-2, PTEN, and EGF-R proteins are found to be
altered (Pinion et al., 1991; Spandidos et al., 2000) and promote
malignant transformation in experimental tumor models
(Boehm et al., 2005; Goessel et al., 2005). These are other
cellular changes that may be required for full transformation of
the HPVEP and E6/E7LX keratinocytes.
In conclusion, we have demonstrated that human cervical
keratinocytes containing stable HPV episomes resist transfor-
mation by H-RasG12V. We are currently developing a model of
how early cervical lesions progress to malignancy using the
HPVEP cells in conjunction with other cervical cancer markers.
These studies will be important for determining the types of
events necessary for HPV-associated transformation and may
point to strategies for inhibiting HPV-related cancer.
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Cell culture
Cell cultures were maintained with post-mitotic, γ-irradiated
J2 3T3 feeder fibroblasts in E-media: 3 parts Dulbecco'smodified
Eagle's media (Invitrogen, Carlsbad, CA) and 1 part HAMs F-12
nutrient mixture (Invitrogen) supplemented with 10% FBS
(Invitrogen), 1% penicillin–streptomycin (Invitrogen), 1.36 ng/
ml tri-iodo-thyronine (Sigma, St. Louis, MO), 0.5 μg/ml
hydrocortisone (Sigma), 8.4 ng/ml cholera toxin (Sigma),
5.0 μg/ml transferrin (Sigma), 5.0 μg/ml insulin (Sigma), and
4.5 ng/ml human-EGF (Invitrogen). Primary human cervical
keratinocytes were isolated as previously described (Blanton et
al., 1991). Prior to splitting and sample collection, irradiated
fibroblasts were removed using a mixture of 0.05% trypsin,
50 mM HEPES buffer in Hanks balanced salt solution
(Invitrogen). Keratinocytes were removed by incubation in
0.05% trypsin/EDTA (Invitrogen) and passed at a 1:4 ratio.
Cell lines
We previously generated human cervical keratinocyte cell
lines containing stable HPV-16 episomes (Sprague et al., 2002),
named HPVEP cells in this paper. Briefly, primary keratinocytes
were co-transfected with circular HPV-16 genomes derived from
W12 subclone E cells (W12-E) and a selectable marker (W12-E
DNA provided by Paul Lambert, University ofWisconsin). After
selection and dilution plating, colonies were isolated by ring
cloning to establish isogenic cell lines (labeled B, F, and G). The
same primary cells were used for transductionswith the retroviral
construct LXSN-16E6/E7 (obtained fromDenise Galloway, Fred
Hutchinson Cancer Research Center (Halbert et al., 1991)) by a
method previously described (Farwell et al., 2000). Isogenic cell
lines were generated from ring-cloned colonies (labeled #2, #5,
and #6) and named E6/E7LX cells. Both HPVEP and E6/E7LX
cells have been passaged over 40 times, equivalent to greater than
100 PD at which point we consider them to be immortalized. Due
to the premise of the paper, we used cells at an earlier passage.
Cells were used at passage 15 (∼30 PD) for retroviral
transductions. The W12 parental cell line (positive for HPV-16
episomes), 1811-NMU-T cells (Klingelhutz et al., 1993), and
C33A cells were used for various controls.
Constitutively active Ras expression was achieved using the
pBabe-puro H-RasG12V retroviral construct (obtained from
Scott Lowe, Cold Spring Harbor Laboratory). The vector was
sequenced to ensure functionality. The concentration for
neomycin selection for LXSN transductions was 100 μg/ml
G418 (Invitrogen). Puromycin (Sigma) was used for three days
at 1 μg/ml after infection of pBabe-puro retroviruses. All
collections and experiments with Ras were performed within
the first 3 passages after final puromycin selection.
Senescent cell count
HPVEP and E6/E7LX cells were plated in triplicate 60-mm
dishes in E-media without feeders and grown to subconfluency.Cell culture microphotographs were taken using a Nikon
Eclipse TE2000 inverted microscope. Enlarged and flattened
cells, indicative of senescence, were tabulated from a blinded
count of triplicate microphotographs. The number of senescent-
like cells was calculated as a percentage of the total number of
cells counted in each field.
Crystal violet assay
Cells were plated in triplicate in a 96-well format at a
concentration of 2000 cells per 150 μl media and media changed
daily. At specific time points, wells were washed with 1× PBS
and stained with a solution of 0.5% crystal violet (w/v) in 20%
methanol for 15min.Wells were washed five times with distilled
water and allowed to air-dry for 45 min or overnight. The cell-
associated dye was extracted with 100 μl of 10% acetic acid and
absorbance was read at λ=595 nm. Population doubling time
was calculated as [time in hours]/[(log N− log NO)/log 2];
N=absorbance value at day 5 and NO=value at day 2.
Southern analysis
Southern analysis was performed as previously described
(Sprague et al., 2002). Briefly, whole cell DNA was isolated
from later passage clonal cultures using the QIAamp DNA
BloodMini Kit (Qiagen, Valencia, CA) and digested either
with BamHI or BglII. DNA was resolved on 1% agarose gels,
depurinated in 0.25 M HCl, and blotted onto positively
charged Hybond-XL nylon membranes (Amersham Bios-
ciences Corp., Piscataway, NJ) by alkaline transfer with
0.4N NaOH. The different forms of HPV DNA were detected
using radioactive probes of PCR-amplified segments of HPV-
16 (nt 6226–3873/4471–6000). Known quantities of HPV
DNA linearized by BamHI were included to estimate the viral
load.
Western analysis
Protein from subconfluent cultures was collected in lysis
buffer as previously described (Foster and Galloway, 1996) and
quantified using the Bio-Rad Protein Assay (Bio-Rad Labora-
tories, Hercules, CA). Western blots were prepared using 30 μg
of protein transferred to polyvinyl difluoride membranes. Blots
were probed with primary antibodies for H-Ras (sc-29, Santa
Cruz), p-MEK1/2 (Ser217/221; #9121, Cell Signaling Technol-
ogy, Danvers, MA), p-44/42 MAPK (Thr202/Tyr204; #9101S,
Cell Signaling Technology), p53 (Ab-6, Oncogene Research),
HPV-16 E7 (#28-0006, Zymed Labs, South San Francisco,
CA), p16 (#554070, Pharmingen) or beta-actin (I-19, Santa
Cruz) and with the appropriate HRP-conjugated secondary
antibodies, either goat anti-mouse IgG (Jackson Immuno-
Research Laboratories), goat anti-rabbit IgG (Santa Cruz), or
donkey anti-goat IgG (Santa Cruz). Chemiluminescence was
detected using the Western Lightning kit (Perkin-Elmer Life
Sciences). All films were scanned with a Hewett-Packard
PrecisionScan 5300 and Adobe Photoshop software. Mem-
branes were stripped by a 30 min, 50 °C incubation in a solution
76 K.L. Berger et al. / Virology 356 (2006) 68–78of 100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM Tris–
HCl at pH 6.7.
Soft agar assay
Polyester membranes of transwell inserts (12-mm diameter,
0.4-μm pore; Costar, Corning, NY) were coated with 100 μl 1%
noble agar. After counting cells using a hemacytometer, 1 part
of 3.3% noble agar at 45 °C was diluted with 10 parts cell
suspension for a final concentration of 700 cells per 400 μl.
Triplicate wells for each cell line expressing Ras or vector
were seeded with 700 cells. After agar solidification, media
were added to the outer wells. After 3 weeks, transwell inserts
were photographed using an Olympus stereoscope. Colonies
approximately 0.19 mm in diameter or greater were tabulated.
For statistical analysis, we compared the overall proportion
(Z-statistic) of soft agar colonies between the Ras-expressing
and vector conditions.
Tumorigenicity
Cells (1×106) in 0.2 ml KSFMwere injected subcutaneously
into 3-week-old female athymic (nu/nu) mice (Harlan-Sprague-
Dawley, Madison, WI). Three mice were used for each Ras-
expressing and each vector control cell line. Mice were housed
in a pathogen-free barrier facility at The University of Iowa and
handled in compliance with federal and institutional
regulations.
Real-time RT-PCR
Total RNA was collected using TRIzol reagent (Invitrogen)
and treated with 1U per μg RNA of DNase I AMP-grade
(Invitrogen) per manufacturer's instructions. The RT reaction
consisted of 1.7 μg RNA, 2 μl random hexamers, and
RetroScript kit reagents (Ambion, Austin, TX) according to
instructions. RNA was reverse transcribed for 1 h at 42 °C
with inactivation at 92 °C for 10 min. Real-time PCR was
performed on cDNA equivalent to 150 ng RNA in triplicate
25 μl reactions using SYBR Green PCR master mix
(#4309155, Applied Biosystems, Foster City, CA) containing
250 nM forward and reverse primers for E6 or E7. Unspliced
HPV16-E6 was detected as described (Lanham et al., 2001).
E6 forward: 5′-CAA ACC GTT GTG TGA TTT GTT AAT
TA-3′; E6 reverse: 5′-GCT TTT TGT CCA GAT GTC TTT
GC-3′ (Integrated DNA Technologies, Coralville, IA).
Sequences for HPV16-E7 primers were provided by Sara
Isabel Pai (Johns Hopkins Medical Institution, MA) (Walboo-
mers et al., 1999). E7 forward: 5′-CCG GAC AGA GCC CAT
TAC AA-3′; E7 reverse: 5′-CGA ATG TCT ACG TGT GTG
CTT TG-3′ (Integrated DNA Technologies). Standardization
was based on 18S levels from reactions using primers at
75 nM final concentration. 18S forward: 5′-CCT TGG ATG
TGG TAG CCC GTT T-3′; 18S reverse: 5′-AAC TTT CGA
TGG TAG TCG CCG-3′ (Sigma-Genosys, The Woodlands,
TX). PCR amplification began at 94 °C for 10 min prior to 30
cycles of 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 1 min.Real-time PCR data were analyzed using the ABI 7000
Sequence Detection System and ABI Prism 7000 SDS
software (Applied Biosystems). Fold differences in oncogene
mRNA levels were calculated relative to the W12 cell line by
using the equation:
21 DDCTð Þ where DDCT ¼ DCW12T  DCcell lineT :
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